HK Stock Market Move | AVICHINA (02357) rose nearly 4% in late trading as the Egypt Airshow catalyzes export expectations; the company is a full-industry-chain aviation technology platform.
AVICHINA (02357) rose nearly 4% in late trading. As of press time, it was up 3.90% at HK$2.93, with a turnover of HK$63.8593 million.
AVICHINA (02357) rose nearly 4% in late trading. As of press time, it was up 3.90% at HK$2.93, with a turnover of HK$63.8593 million.
On the news front, the second Egypt International Airshow recently opened at El Alamein International Airport, with China sending multiple types of active main combat equipment for static display. Orient believes that this participation is expected to intuitively demonstrate the achievements of China's equipment system development, and overseas systematic participation is expected to enhance the recognition of the equipment and export expectations.
HAITONG INT'L pointed out that AVICHINA is the overseas capital operation platform under Aviation Industry Corporation of China (AVIC), having built a full-industry-chain system covering complete aircraft, supporting systems, and aviation engineering services. With aviation supporting systems as its core revenue pillar and growth engine, the company, relying on the technical depth and resource endowments of its parent company AVIC, is accelerating its transformation from a traditional manufacturing state-owned enterprise to a leader in the low-altitude economy ecosystem.
Related Articles

CLSA: Rise of Agentic AI in China, Top Picks TENCENT (00700) and BABA-W (09988)

Financial capital joins hands with AI: OSHIDORI (00622) and Terminus open a new chapter in strategic cooperation.

HK Stock Market Move | ANTENGENE-B(06996) rose over 9% as the first patient was dosed in the pivotal Phase III CLINCH-3 study of ATG-022.
CLSA: Rise of Agentic AI in China, Top Picks TENCENT (00700) and BABA-W (09988)

Financial capital joins hands with AI: OSHIDORI (00622) and Terminus open a new chapter in strategic cooperation.

HK Stock Market Move | ANTENGENE-B(06996) rose over 9% as the first patient was dosed in the pivotal Phase III CLINCH-3 study of ATG-022.

RECOMMEND





